-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $89

Benzinga·05/12/2026 20:58:51
Listen to the news
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $94 to $89.